WO2000078298A3 - Programming ovulation by administering estrogen such as estradiol - Google Patents

Programming ovulation by administering estrogen such as estradiol Download PDF

Info

Publication number
WO2000078298A3
WO2000078298A3 PCT/EP2000/005665 EP0005665W WO0078298A3 WO 2000078298 A3 WO2000078298 A3 WO 2000078298A3 EP 0005665 W EP0005665 W EP 0005665W WO 0078298 A3 WO0078298 A3 WO 0078298A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovulation
programming
estradiol
follicular phase
estrogen
Prior art date
Application number
PCT/EP2000/005665
Other languages
French (fr)
Other versions
WO2000078298A2 (en
Inventor
Ziegler Dominique De
Original Assignee
Columbia Lab Bermuda Ltd
Ziegler Dominique De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd, Ziegler Dominique De filed Critical Columbia Lab Bermuda Ltd
Priority to CA002377609A priority Critical patent/CA2377609C/en
Priority to AU56839/00A priority patent/AU5683900A/en
Priority to MXPA02000127A priority patent/MXPA02000127A/en
Publication of WO2000078298A2 publication Critical patent/WO2000078298A2/en
Publication of WO2000078298A3 publication Critical patent/WO2000078298A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of exogenous estrogen, or a substance that causes estrogen release, in programming ovulation, measuring or controlling follicular phase length, preventing conception, facilitating fertility, therapeutically treating infertility, synchronizing early follicular phase assessments, and scheduling late follicular phase clinical evaluations.
PCT/EP2000/005665 1999-06-21 2000-06-20 Programming ovulation by administering estrogen such as estradiol WO2000078298A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002377609A CA2377609C (en) 1999-06-21 2000-06-20 Programming ovulation
AU56839/00A AU5683900A (en) 1999-06-21 2000-06-20 Programming ovulation
MXPA02000127A MXPA02000127A (en) 1999-06-21 2000-06-20 Programming ovulation.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13978399P 1999-06-21 1999-06-21
US60/139,783 1999-06-21
US59360300A 2000-06-12 2000-06-12
US09/593,603 2000-06-12

Publications (2)

Publication Number Publication Date
WO2000078298A2 WO2000078298A2 (en) 2000-12-28
WO2000078298A3 true WO2000078298A3 (en) 2001-08-02

Family

ID=26837532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005665 WO2000078298A2 (en) 1999-06-21 2000-06-20 Programming ovulation by administering estrogen such as estradiol

Country Status (6)

Country Link
AU (1) AU5683900A (en)
CA (1) CA2377609C (en)
CO (1) CO5180654A1 (en)
MX (1) MXPA02000127A (en)
PE (1) PE20010640A1 (en)
WO (1) WO2000078298A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0710759A (en) * 1993-06-28 1995-01-13 Sekisui Chem Co Ltd Percutaneous absorption pharmaceutical preparation
EP0737477A1 (en) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Percutaneously absorbable preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0710759A (en) * 1993-06-28 1995-01-13 Sekisui Chem Co Ltd Percutaneous absorption pharmaceutical preparation
EP0737477A1 (en) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Percutaneously absorbable preparation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HANDELSMAN, DAVID J. ET AL: "Oestradiol enhances testosterone-induced suppression of human spermatogenesis", HUM. REPROD. (2000), 15(3), 672-679, XP000986414 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 04 31 May 1995 (1995-05-31) *
SALEM, MOHAMED LABIB ET AL: "Beta- estradiol -induced decrease in IL-12 and TNF-.alpha. expression suppresses macrophage functions in the course of Listeria monocytogenes infection in mice", INT. J. IMMUNOPHARMACOL. (1999), 21(8), 481-497, XP000981869 *
SUTTON, D. J. ET AL: "Prevention of pregnancy in bitches following unwanted mating: a clinical trial using low dose estradiol benzoate", J. REPROD. FERTIL., SUPPL. (1997), 51(REPRODUCTION IN DOGS, CATS AND EXOTIC CARNIVORES), 239-243, XP000986432 *
WOOLFSON, A. D. ET AL: "Design of an intravaginal ring for the controlled delivery of 17.beta.- estradiol as its 3-acetate ester", J. CONTROLLED RELEASE (1999), 61(3), 319-328, XP000982079 *

Also Published As

Publication number Publication date
CO5180654A1 (en) 2002-07-30
WO2000078298A2 (en) 2000-12-28
AU5683900A (en) 2001-01-09
CA2377609A1 (en) 2000-12-28
MXPA02000127A (en) 2003-01-28
CA2377609C (en) 2009-04-21
PE20010640A1 (en) 2001-06-06

Similar Documents

Publication Publication Date Title
IL153497A0 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
HUP0004133A3 (en) Combined use of progestin and polycarboxilic acid for the preparation of pharmaceutical compositions for controlled bleeding
AP9801384A0 (en) Improvements of implantation rates after in vitro fertilization.
HUP9900252A2 (en) Pharmaceutical combined preparation, kit for hormonal contraception
HK1048269A1 (en) The use of non-oral androgenic steroids in the manufacture of medicine for improving elevated sex hormone binding globulin levels
ZA987540B (en) Process for the preparation of stanol esters, and use thereof.
ATE241361T1 (en) HORMONAL CONTRACEPTION MEANS
NZ221991A (en) Device for the transdermal delivery of progesterone, estradiol esters and mixtures thereof; and compositions therefor
KR970069031A (en) Pharmaceutical tablets with controlled release of steroids from sugar coating
IL127581A0 (en) Crystal form i of clarithromycin
HUP0200173A2 (en) Combined use of estrogen and progestogen, norethindrone acetate and ethinyl estradiol for preparing pharmaceutical compositions for preventing and treating skin aging and acne
ES2124905T3 (en) ANTIGLUCOCORTICOID STEROIDS INTENDED FOR THE TREATMENT OF ANXIETY DISORDERS.
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
WO2000047603A3 (en) 16-hydroxyestratrienes as selective estrogens
AP2002002475A0 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
HUP0100854A3 (en) Cholenic acid amides, process for their preparation and pharmaceutical compositions thereof
WO2000078298A3 (en) Programming ovulation by administering estrogen such as estradiol
HUP0200134A3 (en) Controlled release formulation for treating copd and process for its preparation
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
HUP0104738A3 (en) Controlled release fertilizer compositions and processes for the preparation thereof
HUP0204324A3 (en) Use of fsh for preparation of pharmaceutical composition suitable for treating infertility
HUP0004033A3 (en) Controlled release fertilizer compositions and processes for the preparation thereof
CA2467964A1 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
WO2003104253A3 (en) 9-alpha-substituted estratrienes as selectively active estrogen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2377609

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000127

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP